Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology and targeted therapies for the treatment of solid tumors. Founded in 2016 and headquartered in San Mateo, California, the company is advancing a diversified pipeline of monoclonal antibodies and small-molecule inhibitors designed to address significant unmet needs in oncology. By leveraging insights into tumor immunology and molecular signaling pathways, Checkpoint Therapeutics aims to bring differentiated cancer therapies to patients across multiple indications.
The company’s lead candidate, cosibelimab, is a human anti–PD-L1 monoclonal antibody being evaluated in various solid tumors, including cutaneous squamous cell carcinoma, Merkel cell carcinoma and urothelial carcinoma. In tandem, Checkpoint is developing targeted therapies against the epidermal growth factor receptor (EGFR), notably its CK-101 and CK-301 programs, which are designed to overcome resistance mechanisms observed in patients with EGFR-driven cancers. These assets underscore Checkpoint’s strategy of combining immuno-oncology approaches with precision medicine to deliver enhanced clinical benefits.
Checkpoint Therapeutics operates in North America, Europe and select Asian markets, collaborating with academic institutions and industry partners to accelerate clinical development and regulatory review. The company’s management team, led by President and Chief Executive Officer Dennis Benjamin and Chief Medical Officer Dr. Adam M. Singer, brings extensive experience in oncology research, clinical development and regulatory affairs. This leadership has guided the company through successful financing rounds, an initial public offering in 2018 and multiple clinical milestones.
Looking ahead, Checkpoint Therapeutics continues to expand its clinical footprint, enrolling patients in late-stage trials while exploring strategic collaborations to broaden its commercial reach. With a clear focus on advancing therapies that harness the immune system and target key tumor drivers, the company remains committed to transforming the treatment landscape for patients with cancer around the world.
AI Generated. May Contain Errors.
Free CKPT Stock Alerts